• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by OneMedNet Corp

    8/5/24 5:15:39 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ONMD alert in real time by email
    SC 13G 1 d11434896_13g.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

     

    OneMedNet Corporation
    (Name of Issuer)

     

     

     

    Common Stock, par value $0.001 per share
    (Title of Class of Securities)

     

     

     

    68270C103
    (CUSIP Number)

     

     

     

    July 25, 2024
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [ ] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    CUSIP No. 68270C103    

     

         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Discovery Capital Management, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [x]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Connecticut  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      2,301,791  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      2,301,791  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      2,301,791  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      8.4%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IA  
             

     

     

     

     
     

     

     

    CUSIP No. 68270C103    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Robert K. Citrone  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [x]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      U.S.A.  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      2,301,791  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      2,301,791  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      2,301,791  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      8.4%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IN, HC  
             

     

     

     
     

     

    CUSIP No. 68270C103    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Discovery Global Opportunity Master Fund, Ltd.  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [x]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Cayman Islands  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      2,301,791  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      2,301,791  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      2,301,791  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      8.4%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      CO  
             

     

     

     
     

     

    CUSIP No. 68270C103    

     

    Item 1. (a). Name of Issuer:
         
        OneMedNet Corporation
         
      (b). Address of Issuer's Principal Executive Offices:
         
       

    6385 Old Shady Oak Road, Suite 250

    Eden Prairie, Minnesota 55344

         
    Item 2. (a) – (c) Name, Principal Business Address, and Citizenship of Persons Filing:
         
        Discovery Capital Management, LLC – Connecticut
       

    Robert K. Citrone – U.S.A.

    Discovery Global Opportunity Master Fund, Ltd. – Cayman Islands

         
       

    Discovery Capital Management, LLC

    20 Marshall Street, Suite 310

    South Norwalk, CT 06854

    United States of America

     

       

    Robert K. Citrone

    c/o Discovery Capital Management, LLC

    20 Marshall Street, Suite 310

    South Norwalk, CT 06854

    United States of America

     

    Discovery Global Opportunity Master Fund, Ltd.

    c/o Discovery Capital Management, LLC

    20 Marshall Street, Suite 310

    South Norwalk, CT 06854

    United States of America

     

         
      (d).   Title of Class of Securities:
         
        Common Stock, par value $0.0001 per share
         
      (e). CUSIP Number:
         
        68270C103
         
    Item 3.   If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a
         
           

     

      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [X] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
     
     

     

      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [X] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).
     
    Item 4. Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
             

     

      (a)   Amount beneficially owned:
         
        Discovery Capital Management, LLC – 2,301,791
       

    Robert K. Citrone – 2,301,791

    Discovery Global Opportunity Master Fund, Ltd. -2,301,791

         
      (b)   Percent of class:
         
        Discovery Capital Management, LLC – 8.4%
       

    Robert K. Citrone – 8.4%

    Discovery Global Opportunity Master Fund, Ltd. – 8.4%

         
      (c)   Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote  
             
          Discovery Capital Management, LLC – 0
         

    Robert K. Citrone – 0

    Discovery Global Opportunity Master Fund, Ltd. - 0

             
        (ii)   Shared power to vote or to direct the vote  
             
          Discovery Capital Management, LLC – 2,301,791
         

    Robert K. Citrone – 2,301,791

    Discovery Global Opportunity Master Fund, Ltd. - 2,301,791

             
        (iii) Sole power to dispose or to direct the disposition of  
             
          Discovery Capital Management, LLC – 0
         

    Robert K. Citrone – 0

    Discovery Global Opportunity Master Fund, Ltd. - 0

             
        (iv)   Shared power to dispose or to direct the disposition of  
             
          Discovery Capital Management, LLC – 2,301,791
         

    Robert K. Citrone – 2,301,791

    Discovery Global Opportunity Master Fund, Ltd. - 2,301,791

     
     

     

     
    Item 5. Ownership of Five Percent or Less of a Class.
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [__].
     
      N/A
       
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
     
      N/A.
       
       

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
     
      See Exhibit B attached hereto.
       
       

     

    Item 8. Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
     
      N/A
       
       

     

    Item 9. Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
     
      N/A
       
       

     

    Item 10. Certification.

     

     
      (a)   Certification by Discovery Capital Management, LLC and Robert K. Citrone:
         
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
         
     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      August 5, 2024
      (Date)
       
       
      Discovery Capital Management, LLC
       
      By:  /s/ Robert K. Citrone
      (Signature)
       
      Managing Member
      (Name/Title)
       
       Discovery Global Opportunity Master Fund, Ltd.
       
      By:  /s/ Robert K. Citrone
      (Signature)
       
      Director
      (Name/Title)
       
      /s/ Robert K. Citrone
      (Signature)

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

     
     

     

    EXHIBIT A

     

    AGREEMENT

     

    The undersigned agree that this Schedule 13G dated August 5, 2024 relating to the Common Stock, par value $0.0001 per share of OneMedNet Corporation shall be filed on behalf of the undersigned.

     

      August 5, 2024
      (Date)
       
       
      Discovery Capital Management, LLC
       
      By:  /s/ Robert K. Citrone
      (Signature)
       
      Managing Member
      (Name/Title)
       
      Discovery Global Opportunity Master Fund, Ltd.
       
      By:  /s/ Robert K. Citrone
      (Signature)
       
      Director
      (Name/Title)
       
      /s/ Robert K. Citrone
      (Signature)

     

     

     

     

     
     

     

    EXHIBIT B

     

    Discovery Capital Management, LLC is the relevant entity for which Robert K. Citrone may be considered a control person.

     

     

     

     

     

     

     

     

     

     

    Get the next $ONMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ONMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ONMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OneMedNet Selects Palantir to Advance Healthcare AI and Data Analytics

    DENVER and MINNEAPOLIS, Oct. 06, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) has selected Palantir Technologies (NASDAQ:PLTR) to transform the healthcare AI and Real-World Data (RWD) analytics marketplace. Palantir's Artificial Intelligence Platform will provide the infrastructure for OneMedNet's iRWD™ near real-time AI powered provider network (‘network') enabling OneMedNet to empower life sciences, medical device, and research organizations with anonymized, regulatory-grade clinical data and advanced analytics to accelerate the development of cutting-edge medical solutions efficiently. Access to healthcare data remains a key barrier to unlocking the $868 billion market

    10/6/25 7:00:00 AM ET
    $ONMD
    $PLTR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Computer Software: Prepackaged Software
    Technology

    OneMedNet Selects Palantir to Advance Healthcare AI and Data Analytics

    OneMedNet Corporation (NASDAQ:ONMD) has selected Palantir Technologies (NASDAQ:PLTR) to transform the healthcare AI and Real-World Data (RWD) analytics marketplace. Palantir's Artificial Intelligence Platform will provide the infrastructure for OneMedNet's iRWD™ near real-time AI powered provider network ("network") enabling OneMedNet to empower life sciences, medical device, and research organizations with anonymized, regulatory-grade clinical data and advanced analytics to accelerate the development of cutting-edge medical solutions efficiently. Access to healthcare data remains a key barrier to unlocking the $868 billion market opportunity in AI-driven healthcare by 20301. OneMedNet is

    10/6/25 6:59:00 AM ET
    $ONMD
    $PLTR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Computer Software: Prepackaged Software
    Technology

    OneMedNet Expands Into $1.5B Healthcare Data Annotation Market With MedCase

    MINNEAPOLIS, Sept. 24, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet," the "Company," "we," "us" or "our"), a leader in AI-powered Real-World Data (RWD), announced a strategic partnership with Medcase, a worldwide network of healthcare professionals focused on medical data annotation. This collaboration establishes a new market entry point for OneMedNet and opens a high-growth revenue channel in the healthcare AI ecosystem. Strategic Expansion into Healthcare Data Annotation The global healthcare data annotation market, valued at $1.5 billion in 2025 and projected to be $2.8 billion by 2030, has entered a pivotal growth phase1. Scale AI's $14.8B investment from

    9/24/25 8:45:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ONMD
    SEC Filings

    View All

    OneMedNet Corp filed SEC Form 8-K: Other Events

    8-K - OneMedNet Corp (0001849380) (Filer)

    9/15/25 8:30:39 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 424B3 filed by OneMedNet Corp

    424B3 - OneMedNet Corp (0001849380) (Filer)

    8/13/25 5:24:56 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-Q filed by OneMedNet Corp

    10-Q - OneMedNet Corp (0001849380) (Filer)

    8/13/25 4:57:25 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ONMD
    Leadership Updates

    Live Leadership Updates

    View All

    Dr. Kenneth Alleyne Joins OneMedNet Board of Directors

    MINNEAPOLIS, March 03, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet"), the leading Real World Data platform powered by AI-driven de-identification, announces the appointment of Dr. Kenneth Alleyne to its Board of Directors. A board-certified orthopedic surgeon specializing in sports medicine, Dr. Alleyne will assume the role of Chair of the Audit Committee, bringing extensive expertise in healthcare, insurance, investment, and corporate governance to the organization. Dr. Alleyne is the managing partner of HartHaven Partners, a healthcare consulting firm supporting private equity and venture capital firms. He co-founded NextLevel Health Partners and Zing Health

    3/3/25 8:35:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OneMedNet Announces Exciting New Collaboration with Bayer's AI Innovation Platform to Help Accelerate Healthcare AI Development

    MINNEAPOLIS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet" or the "Company"), a Real-World Data (RWD) platform — has announced its collaboration with Bayer's AI Innovation Platform (AIIP). By joining AIIP, the partnership aims to empower the developer teams of healthcare organizations and startups in building scalable and compliant AI-powered medical imaging software products. "We are thrilled to join forces with Bayer's AI Innovation Platform," said Aaron Green, CEO & President of OneMedNet. "This collaboration allows us to combine our regulatory-grade real-world data platform, which aggregates data from our provider network of over 1,400 healthcare

    12/2/24 8:30:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OneMedNet appoints new CFO

    MINNEAPOLIS, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet" or the "Company"), the leading curator of regulatory-grade Real World Data (RWD), has announced that Bob Golden has joined the OneMedNet Executive Team as Chief Financial Officer spearheading all aspects of the company's financial and accounting operations while continuing to serve as a member of the Board of Directors. Mr. Golden is a Certified Public Accountant with more than 40 years of experience. Mr. Golden has served as the Managing Partner of Cohen, Bender & Golden LLP since 2015, where he provides consulting, accounting and tax services to middle market businesses and owners. Mr. Golde

    9/10/24 8:45:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ONMD
    Financials

    Live finance-specific insights

    View All

    OneMedNet Reports 80% Reduction in Debt Enabling Focus On Growth

    MINNEAPOLIS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet," the "Company," "we," "us" or "our"), a leader in AI-powered Real-World Data (RWD), announced its financial results for the second quarter ended June 30, 2025, including its significantly improved balance sheet. Second Quarter and First Half 2025 Financial Highlights Improved Balance Sheet: Due to the combination of debt conversions, vendor repayments, and highly discounted debt settlements, total liabilities have been reduced from $19.7 million as of December 31, 2024, to $6.2 million as of June 30, 2025, a reduction of approximately $13.5 million. Additional discounted debt settl

    8/14/25 7:45:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ONMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by OneMedNet Corp

    SC 13G - OneMedNet Corp (0001849380) (Subject)

    11/12/24 3:35:37 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G filed by OneMedNet Corp

    SC 13G - OneMedNet Corp (0001849380) (Subject)

    10/1/24 5:01:18 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G filed by OneMedNet Corp

    SC 13G - OneMedNet Corp (0001849380) (Subject)

    8/5/24 5:15:39 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care